Markers of early vascular aging are not associated with cryptogenic ischemic stroke in the young: A case-control study.


Journal

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
ISSN: 1532-8511
Titre abrégé: J Stroke Cerebrovasc Dis
Pays: United States
ID NLM: 9111633

Informations de publication

Date de publication:
Sep 2022
Historique:
received: 16 05 2022
revised: 27 06 2022
accepted: 09 07 2022
pubmed: 20 7 2022
medline: 25 8 2022
entrez: 19 7 2022
Statut: ppublish

Résumé

We aimed to assess the association between covert atherosclerosis, arterial stiffness, and early-onset cryptogenic ischemic stroke (CIS) in a prospective case-control study. We enrolled 123 young CIS patients (median age 41 years; 42% women) and 123 age- and sex-matched controls. Carotid intima-media thickness (CIMT), Augmentation Index (AIx), central pulse wave velocity (PWV), and subendocardial viability ratio (SEVR) were compared between patients and controls. Conditional logistic regression was used adjusting for age, systolic blood pressure, diastolic blood pressure, current smoking, total cholesterol/high-density lipoprotein cholesterol (Total-C/HDL-C) ratio, and glycated albumin to assess the independent association between CIMT, arterial stiffness and CIS. Patients with higher CIMT and PWV were older, more often men and they had more frequently well-documented risk factors, lower HDL and higher Total-C/HDL-C ratio compared to other tertiles. In univariate comparisons, we found no differences between patients and controls regarding CIMT, AIx, or PWV. In the entire cohort, patients had a significantly lower SEVR compared to controls (146.3%, interquartile range [IQR] 125.7-170.3 vs. 158.0%, IQR 141.3-181.0, P=0.010). SEVR was lower also in women compared to their controls (132.0%, IQR 119.4-156.1 vs. 158.7%, IQR 142.0-182.8, P=0.001) but no significant difference appeared between male patients and male controls. However, after adjusting for comorbidities and laboratory values these significant differences were lost (odds ratio [OR] 1.52, 95% confidence interval [CI] 0.47-4.91) in the entire cohort and OR 3.89, 95% CI 0.30-50.80 in women). Higher CIMT and PWV were associated to higher age, male sex, and several well-documented cardiovascular risk factors. However, in this study we could not prove that either covert atherosclerosis or arterial stiffness contribute to pathogenesis of early-onset CIS.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
We aimed to assess the association between covert atherosclerosis, arterial stiffness, and early-onset cryptogenic ischemic stroke (CIS) in a prospective case-control study.
METHODS METHODS
We enrolled 123 young CIS patients (median age 41 years; 42% women) and 123 age- and sex-matched controls. Carotid intima-media thickness (CIMT), Augmentation Index (AIx), central pulse wave velocity (PWV), and subendocardial viability ratio (SEVR) were compared between patients and controls. Conditional logistic regression was used adjusting for age, systolic blood pressure, diastolic blood pressure, current smoking, total cholesterol/high-density lipoprotein cholesterol (Total-C/HDL-C) ratio, and glycated albumin to assess the independent association between CIMT, arterial stiffness and CIS.
RESULTS RESULTS
Patients with higher CIMT and PWV were older, more often men and they had more frequently well-documented risk factors, lower HDL and higher Total-C/HDL-C ratio compared to other tertiles. In univariate comparisons, we found no differences between patients and controls regarding CIMT, AIx, or PWV. In the entire cohort, patients had a significantly lower SEVR compared to controls (146.3%, interquartile range [IQR] 125.7-170.3 vs. 158.0%, IQR 141.3-181.0, P=0.010). SEVR was lower also in women compared to their controls (132.0%, IQR 119.4-156.1 vs. 158.7%, IQR 142.0-182.8, P=0.001) but no significant difference appeared between male patients and male controls. However, after adjusting for comorbidities and laboratory values these significant differences were lost (odds ratio [OR] 1.52, 95% confidence interval [CI] 0.47-4.91) in the entire cohort and OR 3.89, 95% CI 0.30-50.80 in women).
CONCLUSIONS CONCLUSIONS
Higher CIMT and PWV were associated to higher age, male sex, and several well-documented cardiovascular risk factors. However, in this study we could not prove that either covert atherosclerosis or arterial stiffness contribute to pathogenesis of early-onset CIS.

Identifiants

pubmed: 35849915
pii: S1052-3057(22)00341-X
doi: 10.1016/j.jstrokecerebrovasdis.2022.106647
pii:
doi:

Substances chimiques

Biomarkers 0
Cholesterol, HDL 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106647

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest D.G. has received lecture or advisory honoraria from AstraZeneca, Boehringer Ingelheim, Fresenius, GE Healthcare, and Novo Nordisk, and support to attend medical meetings from CVRx and Sanofi Aventis, T.T.: Academic grants from European Union, Finnish Academy of Sciences, University of Gothenburg, Sahlgrenska University Hospital, Sigrid Juselius Foundation, and Wennerström's Foundation. Research contracts with Bayer, Boehringer Ingelheim, and Bristol Myers Squibb. Advisory board memberships: Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Portola Pharm. Other authors report no conflicts of interest.

Auteurs

Nicolas Martinez-Majander (N)

Department of Neurology, Helsinki University Hospital and Clinical Neurosciences, University of Helsinki, Finland. Electronic address: nicolas.martinez-majander@hus.fi.

Daniel Gordin (D)

Abdominal Center Nephrology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland; Joslin Diabetes Center, Harvard Medical School, Boston, MA, United States.

Lotta Joutsi-Korhonen (L)

Department of Clinical Chemistry, HUSLAB, HUS Diagnostic Centre, Helsinki University Hospital, Helsinki, Finland.

Titta Salopuro (T)

Department of Clinical Chemistry, HUSLAB, HUS Diagnostic Centre, Helsinki University Hospital, Helsinki, Finland.

Krishna Adeshara (K)

Abdominal Center Nephrology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland; Clinical and Molecular Metabolism, Faculty of Medicine Research Programs, University of Helsinki, Helsinki, Finland.

Gerli Sibolt (G)

Department of Neurology, Helsinki University Hospital and Clinical Neurosciences, University of Helsinki, Finland.

Sami Curtze (S)

Department of Neurology, Helsinki University Hospital and Clinical Neurosciences, University of Helsinki, Finland.

Jani Pirinen (J)

Department of Neurology, Helsinki University Hospital and Clinical Neurosciences, University of Helsinki, Finland; HUS Helsinki University Hospital, Porvoo Hospital Area, Internal Medicine, Finland; Department of Clinical Physiology and Nuclear Medicine, HUS Medical Imaging Center, Helsinki University Central Hospital and University of Helsinki, Finland.

Ron Liebkind (R)

Department of Neurology, Helsinki University Hospital and Clinical Neurosciences, University of Helsinki, Finland.

Lauri Soinne (L)

Department of Neurology, Helsinki University Hospital and Clinical Neurosciences, University of Helsinki, Finland.

Tiina Sairanen (T)

Department of Neurology, Helsinki University Hospital and Clinical Neurosciences, University of Helsinki, Finland.

Satu Suihko (S)

Department of Cardiology, Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Finland.

Mika Lehto (M)

Department of Cardiology, Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Finland.

Juha Sinisalo (J)

Department of Cardiology, Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Finland.

Per-Henrik Groop (PH)

Abdominal Center Nephrology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland.

Turgut Tatlisumak (T)

Department of Neurology, Helsinki University Hospital and Clinical Neurosciences, University of Helsinki, Finland; Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, and Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Jukka Putaala (J)

Department of Neurology, Helsinki University Hospital and Clinical Neurosciences, University of Helsinki, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH